Bridging nanoplatform and vaccine delivery, a landscape of strategy to enhance nasal immunity

Teng, Zhuang; Meng, Lingyang; Yang, Junli; He, Zheng; Chen, Xiguang; Liu, Ya

doi:10.1016/j.jconrel.2022.09.044

Cited by 15 publications

(7 citation statements)

References 170 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In preclinical or clinical trials, LNPs are mainly administered through intradermal, subcutaneous, or intramuscular injection, allowing them to target nearby draining lymph nodes and present antigens to T cells, exposing antigens to B cells and activating the immune response. − The two COVID-19 mRNA vaccines currently on the market are administered through intramuscular injection. In regard to tumor vaccines, in addition to the above three pathways, colon administration, nasal drip administration, or intratumoral administration can also improve the targeting and efficacy of LNPs. − The method of needle-free injection can alleviate patient pain while also allowing LNPs to reach immune cells under the skin under the influence of high-pressure sources.…”

Section: Challenges In Lnp Designmentioning

confidence: 99%

Lipid Nanoparticle-Based Delivery System─A Competing Place for mRNA Vaccines

Zhang,

Li,

Zhou

2024

ACS Omega

View full text Add to dashboard Cite

mRNA, as one of the foci of biomedical research in the past decade, has become a candidate vaccine solution for various infectious diseases and tumors and for regenerative medicine and immunotherapy due to its high efficiency, safety, and effectiveness. A stable and effective delivery system is needed to protect mRNAs from nuclease degradation while also enhancing immunogenicity. The success of mRNA lipid nanoparticles in treating COVID-19, to a certain extent, marks a milestone for mRNA vaccines and also promotes further research on mRNA delivery systems. Here, we explore mRNA vaccine delivery systems, especially lipid nanoparticles (LNPs), considering the current research status, prospects, and challenges of lipid nanoparticles, and explore other mRNA delivery systems.

show abstract

Section: Challenges In Lnp Designmentioning

confidence: 99%

Lipid Nanoparticle-Based Delivery System─A Competing Place for mRNA Vaccines

Zhang,

Li,

Zhou

2024

ACS Omega

View full text Add to dashboard Cite

show abstract

“…29 To address these limitations, subunit vaccines that are loaded with antigens ex vivo have been designed and developed to contain only minimal antigenic components of the pathogen, such as selected peptide, protein, or polysaccharide antigens, allowing for more precise vaccine design, safety benefits, and manufacturing. 30–32 Subunit cancer vaccines can directly induce hosts to produce large numbers of antigen-specific T cells and stimulate the immune system against pathogens. 27 However, subunit antigens often demonstrate low immunogenicity, limited uptake by APCs, and insufficient lymphoid tissue targeting.…”

Section: Polymeric Nps For Ex Vivo Subunit Cancer Vaccinesmentioning

confidence: 99%

Polymeric nanoparticle-based nanovaccines for cancer immunotherapy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…IN liposomes can improve the accumulation in the brain of small molecules [ 38 , 39 ], peptides [ 40 ], proteins [ 18 ], and nucleic acids [ 41 ], as well as the systemic exposure to different molecules [ 40 , 42 , 43 , 44 ]. IN liposomes are also a potential approach for vaccine delivery, with the advantages of high patient compliance and low infection risk [ 45 , 46 , 47 ]. Cationic liposomes can be used to deliver vaccine adjuvants to enhance the immune response.…”

Section: Introductionmentioning

confidence: 99%

Recent Advances in Intranasal Liposomes for Drug, Gene, and Vaccine Delivery

2023

View full text Add to dashboard Cite

Liposomes are safe, biocompatible, and biodegradable spherical nanosized vesicles produced from cholesterol and phospholipids. Recently, liposomes have been widely administered intranasally for systemic and brain delivery. From the nasal cavity, liposome-encapsulated drugs and genes enter the systemic circulation primarily via absorption in the respiratory region, whereas they can be directly transported to the brain via the olfactory pathway. Liposomes can protect drugs and genes from enzymatic degradation, increase drug absorption across the nasal epithelium, and prolong the residence time in the nasal cavity. Intranasal liposomes are also a potential approach for vaccine delivery. Liposomes can be used as a platform to load antigens and as vaccine adjuvants to induce a robust immune response. With the recent interest in intranasal liposome formulations, this review discusses various aspects of liposomes that make them suitable for intranasal administration. We have summarized the latest advancements and applications of liposomes and evaluated their performance in the systemic and brain delivery of drugs and genes administered intranasally. We have also reviewed recent advances in intranasal liposome vaccine development and proposed perspectives on the future of intranasal liposomes.

show abstract

Bridging nanoplatform and vaccine delivery, a landscape of strategy to enhance nasal immunity

Cited by 15 publications

References 170 publications

Lipid Nanoparticle-Based Delivery System─A Competing Place for mRNA Vaccines

Lipid Nanoparticle-Based Delivery System─A Competing Place for mRNA Vaccines

Polymeric nanoparticle-based nanovaccines for cancer immunotherapy

Recent Advances in Intranasal Liposomes for Drug, Gene, and Vaccine Delivery

Contact Info

Product

Resources

About